Selnoflast for Atherosclerosis

(RIVULET Trial)

This trial tests a new treatment called selnoflast for individuals with atherosclerosis, a condition where fat clogs the arteries, leading to heart problems. Researchers aim to determine if selnoflast can reduce the risk of major heart events when added to standard treatments. Participants will take either selnoflast or a placebo (a sugar pill) twice daily for 12 weeks. Those diagnosed with atherosclerosis and currently managing it with medication might be suitable for this trial. As a Phase 2 trial, this research measures how well selnoflast works in an initial, smaller group, offering participants a chance to contribute to important advancements in heart health.

The trial does not specify if you need to stop your current medications, but it mentions that participants should be on stable treatment for atherosclerosis with standard-of-care medications. It's best to discuss your specific medications with the trial team.

Research has shown that selnoflast is generally safe for people. In earlier studies, it demonstrated a good safety record. For example, one study identified seventeen manageable side effects among participants. Most importantly, participants tolerated the drug well.

Another study found that selnoflast behaved predictably at different doses, indicating good safety.

Unlike the standard cholesterol-lowering medications like statins, Selnoflast offers a new approach to treating atherosclerosis by targeting inflammation in the arterial walls. This novel mechanism of action sets it apart from current treatments, which primarily focus on reducing lipid levels in the blood. Researchers are particularly excited about Selnoflast's potential to address the root cause of plaque formation, possibly leading to more effective management of atherosclerosis. Additionally, its oral administration twice a day makes it a convenient option for patients.

Research has shown that selnoflast might help treat atherosclerosis, a condition affecting the arteries. Studies have found that selnoflast can lower inflammation markers linked to heart disease, such as IL-6 and hsCRP. One study discovered that selnoflast reduced IL-18 levels by 30%, potentially decreasing artery inflammation. The drug targets inflammation, a major factor in atherosclerosis. These findings suggest that selnoflast could be promising for people with this condition. Participants in this trial will receive either selnoflast or a placebo to further evaluate its effectiveness.¹³⁴⁶⁷